Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play
In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a
